Zobrazeno 1 - 10
of 294
pro vyhledávání: '"VJ Suman"'
Autor:
Mark F. Watson, Jeremy Hoog, Abigail S. Caudle, Erika C. Crouch, Y. Wang, Lisa A. Carey, Mitchell Dowsett, AH Partridge, Kiran Vij, Wajeeha Razaq, Cynthia X. Ma, Anna Weiss, Tina J. Hieken, T Dockter, Amy Tiersten, EP Winer, J. M. Guenther, VJ Suman, H. Maluf, A. M. Leitch, Olwen Hahn, JoAnne Zujewski, Gary Unzeitig, Monica M. Mita, MJ Ellis, Clifford A. Hudis, K. K. Hunt, S Sanati
Publikováno v:
Cancer Research. 81:PD2-10
Background: NET is offered to postmenopausal patients (pts) with clinical stage 2/3 ER+/HER2- BC to promote breast-conserving surgery. Also limited surgical accessibility during the COVID19 pandemic has increased NET utility. Inability to identify ET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f154ece5b9908354e73679927881ed3
https://doi.org/10.1158/1538-7445.sabcs20-pd2-10
https://doi.org/10.1158/1538-7445.sabcs20-pd2-10
Autor:
MP Goetz, Xiaojia Tang, VJ Suman, Kevin J. Thompson, Matthew A. Bockol, Richard M. Weinshilboum, Erin E. Carlson, Jia Yu, L Wang, Judy C. Boughey, Peter T. Vedell, Krishna R. Kalari, A Hossain, Jason P. Sinnwell, MT Kalmbach, T Alaparthi
Publikováno v:
Cancer Research. 79:P3-06
Introduction: The vast majority of cancer patients continue to receive treatments that are minimally informed by omics data. In the case of breast cancer, only ER and HER2 are routinely used for treatment selection. There is a particular need for per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b1544eb002ee6218e037d2cb5ac8882
https://doi.org/10.1158/1538-7445.sabcs18-p3-06-10
https://doi.org/10.1158/1538-7445.sabcs18-p3-06-10
Autor:
Ciara C. O’Sullivan, Prema P. Peethambaram, Timothy J. Moynihan, Roberto A. Leon-Ferre, VJ Suman, Matthew P. Goetz, Karthik V. Giridhar, Tufia C. Haddad, Kathryn J. Ruddy, Charles L. Loprinzi, Grace M. Choong, Timothy J. Hobday, MC Liu
Publikováno v:
Cancer Research. 79:P6-18
Cyclin dependent kinase 4 and 6 inhibitors (CDK4/6i) are standard first line (1L) and second line (2L) treatments of ER+ MBC. However, the optimal treatment strategy after progression on a CDK 4/6i is unknown. Given concern for rapid disease progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6235d4f6ee6367ed72da251ec40c83
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-09
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-09
Autor:
T Alaparthi, Judy C. Boughey, Xiaojia Tang, JN Ingle, L Wang, Matthew A. Bockol, Richard M. Weinshilboum, Jason P. Sinnwell, Peter T. Vedell, Krishna R. Kalari, VJ Suman, Kevin J. Thompson, Erin E. Carlson, Matthew P. Goetz
Publikováno v:
Cancer Research. 79:P1-03
Breast cancer is a heterogeneous disease, and unsupervised clustering approaches using gene expression data have identified 3-6 distinct subtypes of triple negative breast cancer (TNBC). A genomically and clinically distinct subtype of TNBC is referr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::426ff96628ecc298622ca57443820d0e
https://doi.org/10.1158/1538-7445.sabcs18-p1-03-04
https://doi.org/10.1158/1538-7445.sabcs18-p1-03-04
Autor:
MP Goetz, Jordan M. Reese, Igor Chernukhin, VJ Suman, Jason S. Carroll, John R. Hawse, JN Ingle, Elizabeth S. Bruinsma, Adam W Nelson
Publikováno v:
Cancer Research. 77:P3-07
Background: Triple negative breast cancer (TNBC) accounts for approximately 20% of all breast cancer diagnoses. It is the most aggressive form of breast cancer and clinical management is problematic due to lack of available targeted therapies. We hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51e8c3636803c1b0805045234a9bc4b6
https://doi.org/10.1158/1538-7445.sabcs16-p3-07-20
https://doi.org/10.1158/1538-7445.sabcs16-p3-07-20
Autor:
Joel M. Reid, Matthew P. Goetz, C Guo, VJ Suman, Elizabeth S. Bruinsma, Malayannan Subramaniam, AM Bode, J Cheng, Mary J. Kuffel, RA Kudgus, John R. Hawse, Matthew M. Ames, Z Huang
Publikováno v:
Cancer Research. 77:P1-08
Background: The primary mechanism by which tamoxifen (Tam) and its metabolites exert their biologic effects is through estrogen receptor (ER) binding and inhibition of ER signaling. We and others demonstrated that endoxifen (Endx) has greater antitum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf0cc7ca1318be5bfd8f4d7f90e38931
https://doi.org/10.1158/1538-7445.sabcs16-p1-08-03
https://doi.org/10.1158/1538-7445.sabcs16-p1-08-03
Autor:
MJ Ellis, A Tavaarwerk, MP Goetz, Jeremy Hoog, Cynthia X. Ma, Charles Erlichman, Tina J. Hieken, Julie A. Margenthaler, Timothy J. Moynihan, Mark E. Burkard, Michael Naughton, Foluso O. Ademuyiwa, Charles L. Loprinzi, L Doyle, VJ Suman, Tufia C. Haddad, S Sanati, Hussam Al-Kateb, Kiran Vij, Donald W. Northfelt, Richard Gray, Zhanfang Guo, J Han, Rebecca Aft, Lee G. Wilke, Elaine R. Mardis
Publikováno v:
Cancer Research. 76:P5-13
Background Activating mutations in PIK3CA occur in approximately 40% ER+BC. MK-2206 (M), a pan-AKT inhibitor, induced apoptosis of ER+ BC under estrogen deprivation in preclinical studies. We conducted this neoadjuvant trial to determine the patholog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e0e5074a5c885f04fa9c77c7c53175d
https://doi.org/10.1158/1538-7445.sabcs15-p5-13-04
https://doi.org/10.1158/1538-7445.sabcs15-p5-13-04
Autor:
Matthew P. Goetz, RW Weinshilboum, Judy C. Boughey, Kirsten Timms, Donald W. Northfelt, Amy Lynn Conners, Eric D. Wieben, Ann M. Moyer, DW Visscher, J Jones, Richard Gray, Travis J. Dockter, Sarah A. McLaughlin, Steven N. Hart, L Wang, EP Elkin, JN Ingle, A-R Hartman, Xiaojia Tang, Sara J. Felten, Peter T. Vedell, A Moreno Aspitia, Krishna R. Kalari, VJ Suman, Katie N. Jones
Publikováno v:
Cancer Research. 76:P3-07
Background: Both HR deficiency and BRCA mutation status predict response to platinum-based therapy and BRCA mutation status predicts docetaxel resistance. However, the association of either biomarker with response to the individual elements of either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f81cdde8e70de64340a8f153403c1895
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-29
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-29
Publikováno v:
Cancer Research. 76:P6-13
Background: During tumor progression, activation of Aurora A kinase (AURKA) is associated with epithelial to mesenchymal transition (EMT) reprogramming and expansion of a subpopulation of tumor initiating cells harboring a CD44+/CD24low/- phenotype [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40e22cdec500dfe9c606c6d1262538b
https://doi.org/10.1158/1538-7445.sabcs15-p6-13-04
https://doi.org/10.1158/1538-7445.sabcs15-p6-13-04
Autor:
Judy C. Boughey, Katie N. Jones, Jason P. Sinnwell, JN Ingle, Richard Gray, Donald W. Northfelt, DW Visscher, Richard M. Weinshilboum, Iii Copland Ja, Sara J. Felten, Ping Yin, Ann M. Moyer, L Wang, Jia Yu, Zhenkun Lou, Matthew P. Goetz, TJ Docter, Kevin J. Thompson, Bo Qin, VJ Suman, A Moreno Aspitia, Sarah A. McLaughlin, Eric D. Wieben, Krishna R. Kalari, Amy Lynn Conners
Publikováno v:
Cancer Research. 76:P3-07
Background: Tumorigenesis involves both genetic and epigenetic changes. Epigenetic alterations are reversible and are promising cancer therapeutic targets. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferase inhibitor, is FDA approved for he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04b00a6350a869be8d7fe4dce4c932ea
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-51
https://doi.org/10.1158/1538-7445.sabcs15-p3-07-51